Sho Yamasaki

Sho Yamasaki

Auto-generated profile, based on publicly available information

Sho Yamasaki

Department of Environmental Medicine and Infectious Diseases, Faculty of Medical Sciences Kyushu University Fukuoka Japan

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 March 2010 in Archives of Virology
Verified
Journal Article
Closed access
PDF file
SYS. Yamasaki
S. Yamasaki
JSJ. Sakai
J. Sakai
SFS. Fuji
S. Fuji
SKS. Kamisoyama
S. Kamisoyama
KEK. Emoto
K. Emoto
KHKentaro Hanada
Kentaro Hanada

16 November 2023 in Journal of Infection and Chemotherapy
Verified
Journal Article
Closed access
YMYuji Matsumoto
Yuji Matsumoto
MMMasayuki Murata
Masayuki Murata
AOAzusa Ohta
Azusa Ohta
SYSho Yamasaki
Sho Yamasaki
HIHiroaki Ikezaki
Hiroaki Ikezaki
NSNobuyuki Shimono
Nobuyuki Shimono

7 August 2024 in BMJ Open
Verified
Journal Article
Open access
PDF file
SYSho Yamasaki
Sho Yamasaki
MMMasayuki Murata
Masayuki Murata
AOAzusa Ohta
Azusa Ohta
YMYuji Matsumoto
Yuji Matsumoto
HIHiroaki Ikezaki
Hiroaki Ikezaki
NFNorihiro Furusyo
Norihiro Furusyo
Objectives: To assess the utility of Helicobacter pylori antibody testing, we evaluated the correlation between the H. pylori antibody titre and H. pylori -associated pathogenicity and the changes in antibody titre after H. pylori eradication therapy. Design: A retrospective observational cohort study. Setting and participants: From 2004 to 2016, medical check-ups were performed in different regions of Japan. In total, 324 subjects infected with H. pylori who received H. pylori eradication therapy were enrolled; H. pylori was eradicated in 266 of these subjects. We examined the associations between H. pylori antibody titre with pepsinogen and the presence or absence of H. pylori -associated pathogenic proteins, such as cytotoxin-associated gene A and vacuolating cytotoxin gene A, at baseline and after H. pylori eradication therapy. Results: The H.pylori antibody titre showed a positive correlation with pepsinogen II and a negative correlation with the pepsinogen I/II ratio. Moreover, the H.pylori antibody titre significantly correlated with the positive rates of H. pylori -associated pathogenic protein before eradication therapy. Antibody titres decreased after eradication, the pepsinogen I/II ratio increased and the H. pylori -associated pathogenic protein-positive rate decreased in patients with successful eradication. The determination of eradication using the decline in antibody titre 6 months after eradication therapy was useful (area under the receiver operating characteristic curve: 0.98). Conclusions: Our data indicate that the H. pylori antibody titre may represent the degree of pathogenicity. The H. pylori antibody titre was associated with attenuation of pathogenicity in patients with H. pylori eradication, indicating the clinical utility of H. pylori antibody testing.

24 May 2025 in Journal of Infection and Chemotherapy
Verified
Journal Article
Closed access
YDYuko Danzuka
Yuko Danzuka
KNKeiji Nakamura
Keiji Nakamura
SMShinya Matsumoto
Shinya Matsumoto
YEYoshitaka Etoh
Yoshitaka Etoh
SYSho Yamasaki
Sho Yamasaki
NSNobuyuki Shimono
Nobuyuki Shimono

30 September 2026 in HIV Medicine
Verified
Journal Article
Closed access
MMMasayuki Murata
Masayuki Murata
YMYuji Matsumoto
Yuji Matsumoto
KTKoji Takayama
Koji Takayama
SYSho Yamasaki
Sho Yamasaki
KYKen Yamamoto
Ken Yamamoto
KSKosaku Sasaki
Kosaku Sasaki